HIV Glasgow 2020

5-8 October 2020 - Virtual Congress


At this year’s HIV Glasgow conference, we proudly presented over 16 abstracts.

Take a look at the table below, which highlights some of the data that was presented at HIV Glasgow 2020.

Please note that only HIV Glasgow 2020 registered delegates are currently able to access this content. Public access to all HIV Glasgow abstracts is available in the congress abstracts book here.


Abstract title
Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)
Oral presentation
The relationship between smoking, CD4, viral load and cancer risk in HIV-positive adults (OIs)
Oral presentation
Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): the STAT study Poster View
Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection: 3-year results from the GEMINI studies Poster View
Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2 Poster View
12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort Poster View
Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany Poster View
The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: results from the EuroSIDA study Poster View
Evaluation and clinical application of fostemsavir* co-administration with tuberculosis medications Poster View
Clinical significance of gp120 polymorphisms, temsavir IC50 FC, and HIV-1 subtype in BRIGHTE
* Fostemsavir is currently only approved for use in the United States
Poster View
Fostemsavir* and ethinyl estradiol drug interaction: clinical application for co-administration Poster View
Fostemsavir* exposure-response relationships in treatment experienced HIV patients Poster View
*Fostemsavir is currently only approved for use in the United States


Positive Perspectives Wave 2 advisors Brent Allan, Erika Castellanos and Bruce Richman explain the research objectives and how the results may encourage discussions around quality of life and a ‘4th 90’ target for people living with HIV. For information on the Positive Perspectives Wave 2 study click here.

Abstract title
Beyond viral load: exploring mediating factors for the gap in optimal self-rated health by adherence status among older adults living with HIV
Social, psychological, and treatment-related challenges of a new HIV diagnosis in old age
What about me? The unmet needs of MSW & differences in HIV treatment experiences, perceptions, and behaviour by gender and sexual orientation in 25 countries Poster View
Self-care and involvement in managed care among people living with HIV in Europe Poster View

For people living with HIV. Resources and information about living well with HIV.

For news and media. Latest news and press releases via our media centre.

For healthcare professionals, Information about ViiV medicines and data.